Relationship between Kaposi's varicelliform eruption in Japanese patients with atopic dermatitis treated with tacrolimus ointment and genetic polymorphisms in the IL-18 gene promoter region

Kouji Osawa, Takafumi Etoh, Noritaka Ariyoshi, Itsuko Ishii, Michteru Ohtani, Satoru Kariya, Katsuyoshi Uchino, Mitsukazu Kitada

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Kaposi's varicelliform eruption is the most important problem in treating patients with atopic dermatitis (AD) with tacrolimus ointment. It has been considered that Kaposi's varicelliform eruption occurs due to decreased levels of interleukin (IL)-18. The aim of this study was to examine the relationship between Kaposi's varicelliform eruption and genetic polymorphisms in the IL-18 gene. IL-18 gene promoter polymorphisms were analyzed in 21 AD patients treated with tacrolimus ointment and in 100 healthy volunteers. Six AD patients with Kaposi's varicelliform eruption during the treatment with tacrolimus ointment showed significantly higher frequency in G-to-C mutations at the IL-18 gene promoter region -137 compared with 15 AD patients without Kaposi's varicelliform eruption. The 15 AD patients without Kaposi's varicelliform eruption as well as 100 healthy volunteers did not have mutations of G-to-C at the IL-18 gene promoter region -137. These results suggest that the onset of Kaposi's varicelliform eruption following the treatment with tacrolimus ointment is associated with the mutation of G-to-C in the IL-18 gene promoter region -137, and that caution is required when using tacrolimus ointment for treating AD patients with this mutation.

Original languageEnglish
Pages (from-to)531-536
Number of pages6
JournalJournal of Dermatology
Volume34
Issue number8
DOIs
Publication statusPublished - Aug 2007
Externally publishedYes

Fingerprint

Kaposi Varicelliform Eruption
Interleukin-18
Tacrolimus
Genetic Polymorphisms
Atopic Dermatitis
Ointments
Genetic Promoter Regions
Genes
Mutation
Healthy Volunteers

Keywords

  • Atopic dermatitis
  • Interferon (IFN)-γ
  • Interleukin (IL)-18
  • Kaposi's varicelliform eruption
  • Tacrolimus ointment

ASJC Scopus subject areas

  • Dermatology

Cite this

Relationship between Kaposi's varicelliform eruption in Japanese patients with atopic dermatitis treated with tacrolimus ointment and genetic polymorphisms in the IL-18 gene promoter region. / Osawa, Kouji; Etoh, Takafumi; Ariyoshi, Noritaka; Ishii, Itsuko; Ohtani, Michteru; Kariya, Satoru; Uchino, Katsuyoshi; Kitada, Mitsukazu.

In: Journal of Dermatology, Vol. 34, No. 8, 08.2007, p. 531-536.

Research output: Contribution to journalArticle

Osawa, Kouji ; Etoh, Takafumi ; Ariyoshi, Noritaka ; Ishii, Itsuko ; Ohtani, Michteru ; Kariya, Satoru ; Uchino, Katsuyoshi ; Kitada, Mitsukazu. / Relationship between Kaposi's varicelliform eruption in Japanese patients with atopic dermatitis treated with tacrolimus ointment and genetic polymorphisms in the IL-18 gene promoter region. In: Journal of Dermatology. 2007 ; Vol. 34, No. 8. pp. 531-536.
@article{e6c0417dcbb84a209d2550e0a4ca6705,
title = "Relationship between Kaposi's varicelliform eruption in Japanese patients with atopic dermatitis treated with tacrolimus ointment and genetic polymorphisms in the IL-18 gene promoter region",
abstract = "Kaposi's varicelliform eruption is the most important problem in treating patients with atopic dermatitis (AD) with tacrolimus ointment. It has been considered that Kaposi's varicelliform eruption occurs due to decreased levels of interleukin (IL)-18. The aim of this study was to examine the relationship between Kaposi's varicelliform eruption and genetic polymorphisms in the IL-18 gene. IL-18 gene promoter polymorphisms were analyzed in 21 AD patients treated with tacrolimus ointment and in 100 healthy volunteers. Six AD patients with Kaposi's varicelliform eruption during the treatment with tacrolimus ointment showed significantly higher frequency in G-to-C mutations at the IL-18 gene promoter region -137 compared with 15 AD patients without Kaposi's varicelliform eruption. The 15 AD patients without Kaposi's varicelliform eruption as well as 100 healthy volunteers did not have mutations of G-to-C at the IL-18 gene promoter region -137. These results suggest that the onset of Kaposi's varicelliform eruption following the treatment with tacrolimus ointment is associated with the mutation of G-to-C in the IL-18 gene promoter region -137, and that caution is required when using tacrolimus ointment for treating AD patients with this mutation.",
keywords = "Atopic dermatitis, Interferon (IFN)-γ, Interleukin (IL)-18, Kaposi's varicelliform eruption, Tacrolimus ointment",
author = "Kouji Osawa and Takafumi Etoh and Noritaka Ariyoshi and Itsuko Ishii and Michteru Ohtani and Satoru Kariya and Katsuyoshi Uchino and Mitsukazu Kitada",
year = "2007",
month = "8",
doi = "10.1111/j.1346-8138.2007.00326.x",
language = "English",
volume = "34",
pages = "531--536",
journal = "Journal of Dermatology",
issn = "0385-2407",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Relationship between Kaposi's varicelliform eruption in Japanese patients with atopic dermatitis treated with tacrolimus ointment and genetic polymorphisms in the IL-18 gene promoter region

AU - Osawa, Kouji

AU - Etoh, Takafumi

AU - Ariyoshi, Noritaka

AU - Ishii, Itsuko

AU - Ohtani, Michteru

AU - Kariya, Satoru

AU - Uchino, Katsuyoshi

AU - Kitada, Mitsukazu

PY - 2007/8

Y1 - 2007/8

N2 - Kaposi's varicelliform eruption is the most important problem in treating patients with atopic dermatitis (AD) with tacrolimus ointment. It has been considered that Kaposi's varicelliform eruption occurs due to decreased levels of interleukin (IL)-18. The aim of this study was to examine the relationship between Kaposi's varicelliform eruption and genetic polymorphisms in the IL-18 gene. IL-18 gene promoter polymorphisms were analyzed in 21 AD patients treated with tacrolimus ointment and in 100 healthy volunteers. Six AD patients with Kaposi's varicelliform eruption during the treatment with tacrolimus ointment showed significantly higher frequency in G-to-C mutations at the IL-18 gene promoter region -137 compared with 15 AD patients without Kaposi's varicelliform eruption. The 15 AD patients without Kaposi's varicelliform eruption as well as 100 healthy volunteers did not have mutations of G-to-C at the IL-18 gene promoter region -137. These results suggest that the onset of Kaposi's varicelliform eruption following the treatment with tacrolimus ointment is associated with the mutation of G-to-C in the IL-18 gene promoter region -137, and that caution is required when using tacrolimus ointment for treating AD patients with this mutation.

AB - Kaposi's varicelliform eruption is the most important problem in treating patients with atopic dermatitis (AD) with tacrolimus ointment. It has been considered that Kaposi's varicelliform eruption occurs due to decreased levels of interleukin (IL)-18. The aim of this study was to examine the relationship between Kaposi's varicelliform eruption and genetic polymorphisms in the IL-18 gene. IL-18 gene promoter polymorphisms were analyzed in 21 AD patients treated with tacrolimus ointment and in 100 healthy volunteers. Six AD patients with Kaposi's varicelliform eruption during the treatment with tacrolimus ointment showed significantly higher frequency in G-to-C mutations at the IL-18 gene promoter region -137 compared with 15 AD patients without Kaposi's varicelliform eruption. The 15 AD patients without Kaposi's varicelliform eruption as well as 100 healthy volunteers did not have mutations of G-to-C at the IL-18 gene promoter region -137. These results suggest that the onset of Kaposi's varicelliform eruption following the treatment with tacrolimus ointment is associated with the mutation of G-to-C in the IL-18 gene promoter region -137, and that caution is required when using tacrolimus ointment for treating AD patients with this mutation.

KW - Atopic dermatitis

KW - Interferon (IFN)-γ

KW - Interleukin (IL)-18

KW - Kaposi's varicelliform eruption

KW - Tacrolimus ointment

UR - http://www.scopus.com/inward/record.url?scp=34547812604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547812604&partnerID=8YFLogxK

U2 - 10.1111/j.1346-8138.2007.00326.x

DO - 10.1111/j.1346-8138.2007.00326.x

M3 - Article

C2 - 17683383

AN - SCOPUS:34547812604

VL - 34

SP - 531

EP - 536

JO - Journal of Dermatology

JF - Journal of Dermatology

SN - 0385-2407

IS - 8

ER -